 |
|
Authors’ Reply to Bayer’s Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis"
Bruce M. Psaty, MD, PhD;
Curt D. Furberg, MD, PhD;
Wayne A. Ray, PhD;
Noel S. Weiss, MD, DrPH
JAMA. 2004;292:2658-2659. Published online November 22, 2004 (doi:10.1001/jama.292.21.2658)
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
The published literature on drug safety in general and the HMG-CoA reductase inhibitors (statins) in general is a matter of public record. These publications have helped to shape our views, and all of us have actively contributed to the public discussion.1-3 In our work with plaintiffs’ attorneys, we reviewed confidential company documents, and we were bound by protective order to keep this information confidential unless that information became public through another means, as indeed some of it did in the Haltom trial. For our review, we used only publicly available documents. Bayer alone can decide whether additional documents can or should be made available for public scrutiny.
In terms of cerivastatin and the risk of rhabdomyolysis, the key questions are when did the spontaneous adverse event reports unequivocally suggest an increased . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
, , , , , , , , , and
JAMA. ;292():2585-2590.
FULL TEXT
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis
, , , and
JAMA. ;292():2622-2631.
FULL TEXT
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: A Counterpoint
JAMA. ;292():2643-2646.
FULL TEXT
Postmarketing Surveillance--Lack of Vigilance, Lack of Trust
, , and
JAMA. ;292():2647-2650.
FULL TEXT
Bayer's Response to "Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis"
JAMA. ;292():2655-2657.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief et al.
Arch Intern Med 2006;166:155-160.
ABSTRACT
| FULL TEXT
Post-Marketing Drug Safety: Keep Patients Your Priority
Dugdale
DOC News 2005;2:3-3.
FULL TEXT
Statins and Rhabdomyolysis -- Clinical Data, Health Policy, and Politics
JWatch General 2005;2005:2-2.
FULL TEXT
Postmarketing Surveillance--Lack of Vigilance, Lack of Trust
Fontanarosa et al.
JAMA 2004;292:2647-2650.
FULL TEXT
|
